hero
Dermbits
Welcome to Dermbits! Watch short videos of KOLs answering your questions
What is the single most meaningful management decision that becomes clearer after genomic testing?

Precision Medicine

What is the single most meaningful management decision that becomes clearer after genomic testing?

Featuring David Cotter, MD, PhD

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Precision Medicine

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Featuring David Cotter, MD, PhD

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Precision Medicine

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Featuring David Cotter, MD, PhD

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Precision Medicine

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Featuring David Cotter, MD, PhD

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

Precision Medicine

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

Featuring David Cotter, MD, PhD

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Precision Medicine

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Featuring David Cotter, MD, PhD

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Precision Medicine

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Featuring David Cotter, MD, PhD

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Precision Medicine

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Featuring David Cotter, MD, PhD

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

Precision Medicine

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

Featuring David Cotter, MD, PhD

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Precision Medicine

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Featuring David Cotter, MD, PhD

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Precision Medicine

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Featuring David Cotter, MD, PhD

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

Precision Medicine

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

Featuring David Cotter, MD, PhD

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

Precision Medicine

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

Featuring David Cotter, MD, PhD

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

Psoriasis

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

Featuring Neal Bhatia, MD

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

Psoriasis

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

Featuring Neal Bhatia, MD

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

Psoriasis

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

Featuring Neal Bhatia, MD

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

Psoriasis

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

Featuring Neal Bhatia, MD

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

Psoriasis

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

Featuring Neal Bhatia, MD

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

Psoriasis

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

Featuring Neal Bhatia, MD

What clinical details make an appeal letter more persuasive?

Atopic Dermatitis

What clinical details make an appeal letter more persuasive?

Featuring Dawn Merritt, DO

What supporting materials help overturn a denial?

Atopic Dermatitis

What supporting materials help overturn a denial?

Featuring Dawn Merritt, DO

When do you escalate from prior auth to formal appeal?

Atopic Dermatitis

When do you escalate from prior auth to formal appeal?

Featuring Dawn Merritt, DO

What’s one documentation habit that consistently improves approvals?

Atopic Dermatitis

What’s one documentation habit that consistently improves approvals?

Featuring Dawn Merritt, DO

How do you document steroid failure before prescribing ruxolitinib cream?

Atopic Dermatitis

How do you document steroid failure before prescribing ruxolitinib cream?

Featuring Dawn Merritt, DO

24 of 925